Background-Atrial fibrosis, a common feature of atrial fibrillation, is thought to originate from the differential response of atrium versus ventricle to pathological insult. However, detailed mechanisms underlying the regional differences remain unclear. The aim of this study was to investigate the related factor(s) in mediating atrial vulnerability to fibrotic processes. Methods and Results-We first compared the response of cultured atrial versus ventricular fibroblasts with transforming growth factor-β (TGF-β), a key mediator of myocardial fibrosis. Atrial fibroblasts showed a stronger response to TGF-β1 in producing extracellular matrix protein (collagen and fibronectin) than ventricular fibroblasts. Furthermore, TGF-β1 activated its downstream signaling (Smads) and induced pronounced oxidative stress, including up-regulation of nicotinamide adenine dinucleotide phosphate oxidase in atrial fibroblasts, and to a lesser extent in ventricular fibroblasts. Nicotinamide adenine dinucleotide phosphate oxidase inhibitors and small-interfering RNA for Nox4 eliminated TGF-β-induced difference between atrial and ventricular fibroblasts, suggesting the crucial role of Nox4 in mediating the atrial-ventricular discrepancy. Small-interfering RNA for Smad3 also suppressed the differential responsiveness of atrial versus ventricular fibroblasts to TGF-β1, including Nox4 activation, implicating a crosstalk between nicotinamide adenine dinucleotide phosphate oxidases and Smad. In vivo, the increased TGF-β1 responsiveness and Nox4 expression were documented in the atria of transgenic mice with cardiac overexpression of TGF-β1. Conclusions-Atrial fibroblasts show greater fibrotic and oxidative responses to TGF-β1 than ventricular fibroblasts. Nox4-derived reactive oxygen species production mediates the susceptibility of atrial fibroblasts to TGF-β1 via activating TGF-β1/Smad signaling cascade, which provides a novel insight into the pathogenesis of atrial fibrosis. (Circ Arrhythm Electrophysiol. 2013;6:790-798.)
A trial fibrillation (AF) is the most common sustained arrhythmia in clinical settings. 1 Atrial fibrosis, involving nonmyocyte growth and extracellular matrix protein deposition, plays a critical role in the pathogenesis of AF. 2 Atrial fibroblasts, which constitute the major component of nonmyocytes, are the main origin of extracellular matrix proteins in the atrium. 2 Emerging evidence suggests that atrial fibroblasts behave differently from ventricular fibroblasts in response to fibrotic insult. 3, 4 In comparison with ventricular fibrosis, atrial fibrosis is more prone to develop in a variety of animal models. [5] [6] [7] [8] Therefore, investigation of the mechanisms underlying the differential behavior between ventricular and atrial fibroblasts may be important for understanding the pathogenesis of AF.
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Transforming growth factor β (TGF-β) is a major contributor to atrial fibrosis. 2 TGF-β1 activates atrial fibroblasts and promotes their differentiation into myofibroblasts, which in return stimulates the production of extracellular matrix proteins, such as collagen I, III, and fibronectin. 2 Transgenic mice with cardiac overexpression of TGF-β1 show selective atrial fibrosis and AF property despite equivalent TGF-β1 expression in the atria and ventricles. 5, 6 It is conceivable that the differential responsiveness of atrial versus ventricular fibroblasts to TGF-β1 may determine atrial vulnerability to fibrosis.
Numerous clinical and experimental studies have associated oxidative stress with the pathogenesis of AF, especially in relation to atrial fibrosis. [9] [10] [11] [12] [13] [14] [15] [16] Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Noxs) by producing reactive oxygen species (ROS) have emerged as the major source of oxidative stress in the atrium. [9] [10] [11] [12] [13] [14] [15] [16] Because oxidative stress induced by TGF-β1 may contribute to the development of atrial fibrosis, 2 we hypothesize that NADPH oxidase-derived ROS may participate in the differential susceptibility to atrial versus ventricular fibrosis.
We first evaluated in parallel the fibrotic response of atrial and ventricular fibroblasts to TGF-β1, especially focusing on extracellular matrix protein expression. We then compared TGF-β1-induced NADPH oxidase-derived ROS production between atrial and ventricular fibroblasts and explored the potential role of NADPH oxidases in mediating TGF-β1 Figure 1 . A, After 24 hours of serum deprivation, cardiac fibroblasts were treated with or without 5 ng/mL TGF-β1 for 24 hours. The expression of fibronectin, collagen I, III, Nox2/4, p-Smad3, and tubulin protein was evaluated by western blot as described in Materials and Methods. The expression of tubulin was used as an internal control. B, The relative expression levels of indicated proteins were quantified by densitometry and normalized to the control level, which was set at 1.0. Each value represents the mean±SE of 4 independent experiments. P<0.05; *represents the significant difference among groups. Nox2/4 indicates nicotinamide adenine dinucleotide phosphate oxidase 2/4; and TGF-β1, transforming growth factor β1. Figure 2 . A, Intracellular ROS production was measured by fluorescent DCF dye as described in Materials and Methods. After 24 hours of serum deprivation, cardiac fibroblasts were treated with or without 5 ng/mL TGF-β1. Time-dependent changes of intracellular reactive oxygen species are shown. B, An identical paradigm was followed as described in A. After 24 hours of serum deprivation, atrial fibroblasts were preincubated with Nox inhibitors (plumbagin, DPI, and gp91-dstat) for 2 hours and subsequently treated with 5 ng/mL TGF-β1. C, An identical paradigm was followed as described in A. After deprivation of serum and transfection of indicated siRNAs for 48 hours, atrial fibroblasts were treated with 5 ng/mL TGF-β1. Each value represents the mean±SE of 4 independent experiments. P<0.05; *, †,#represent the significant differences among groups. DPI indicates diphenyleneiodonium; Nox, nicotinamide adenine dinucleotide phosphate oxidase; si, small interfering; and TGF-β1, transforming growth factor β1.
signaling. Finally, we sought to determine whether the findings obtained in vitro could be verified in transgenic mice with cardiac overexpression of TGF-β1.
Materials and Methods
Complete details are presented in the online-only Data Supplement, expanded Methods section.
Cell Cultures
Atrial and ventricular fibroblasts were obtained from left atria and ventricles of adult male Wistar rats (euthanized with ketamine [100 mg/kg] and xylazine [11.5 mg/kg], IP) using the collagenase and trypsin digestion methods.
MHC-TGFcys33ser Transgenic Mice
The MHC-TGFcys33ser transgenic mice (generous gift from Loren J. Field, James Whitcomb Riley Hospital for Children, IN) are generated by the mouse α-cardiac MHC promoter and sequences encoding the human TGF-β1 cDNA as described.
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Results
TGF-β1 Induces Different Responses Between Atrial and Ventricular Fibroblasts
We first compared the effect of TGF-β1 on cultured atrial versus ventricular fibroblasts. Treatment of atrial fibroblasts with TGF-β1 induced the expression of collagen and fibronectin, 2 major cardiac extracellular matrix proteins.
2 Atrial fibroblasts Figure 3 . A, After 24 hours of serum deprivation, atrial fibroblasts were preincubated with Nox inhibitors (plumbagin, DPI, and gp91-dstat) for 2 hours and subsequently treated with or without 5 ng/mL TGF-β1 for 24 hours. B, After deprivation of serum and transfection of indicated siRNAs for 48 hours, atrial fibroblasts were treated with or without 5 ng/mL TGF-β1. The expression of fibronectin, collagen I, Nox4, p-Smad3, and tubulin protein was evaluated by western blot. C, The relative expression levels of indicated proteins were quantified by densitometry and normalized to the control level. D, After deprivation of serum and transfection of indicated plasmids for 24 hours, cardiac fibroblasts were treated with or without 5 ng/mL TGF-β1. The expression of indicated protein was evaluated by western blot. Each value represents the mean±SE from 4 independent experiments. P<0.05; *, †,#represent the significant differences among groups. DPI indicates diphenyleneiodonium; Nox, nicotinamide adenine dinucleotide phosphate oxidase; siRNAs, small-interfering RNAs; and TGF-β1 indicates transforming growth factor β1.
showed a stronger response to TGF-β1 in producing collagen I, III, and fibronectin than ventricular fibroblasts ( Figure 1A and 1B). However, there was no difference in the distribution/ expression of TGF-β1 receptor between atrial and ventricular fibroblasts ( Figure 1 in the the online-only Data Supplement). Because Smad3 is the main downstream target of TGF-β1, 17 we further assessed the effect of TGF-β1 on the activation of Smad3 using a specific antibody against phospho-Smad3. TGF-β1 increased phospho-Smad3 expression in atrial but not in ventricular fibroblasts ( Figure 1A and 1B). Previous study shows that TGF-β1 stimulates Nox4-derived ROS production and thereby activates cardiac fibroblast. 18 Both Nox2 and Nox4 are the main isoforms of NADPH oxidases in the myocardium. 19 Therefore, we assessed the effect of TGF-β1 on the expression of Nox2/4 and ROS production in atrial and ventricular fibroblasts. The expression of Nox4 and its activity was significantly increased by TGF-β1 treatment in atrial but less in ventricular fibroblasts, and Nox2 expression was unaffected in both fibroblasts (Figure 1A and 1B; Figure 2 in the the online-only Data Supplement). Consistent with Nox4 up-regulation, TGF-β1 robustly enhanced ROS formation in atrial fibroblasts, with a much smaller response in ventricular fibroblasts ( Figure 2A ). The ROS-enhancing effect of TGF-β1 in atrial fibroblasts was attenuated by 10 μmol/L diphenyleneiodonium (DPI; a nonspecific NADPH oxidase inhibitor) and 10 μmol/L plumbagin (a specific Nox4 inhibitor), but to a lesser extent by 50 μmol/L gp91-dstat (a specific Nox2 inhibitor; Figure 2B ; Figure 3 in the the onlineonly Data Supplement), supporting the essential role of Nox4 in TGF-β1-induced ROS production. To further confirm the involvement of Nox4 and Smad3 in TGF-β1-induced ROS elaboration, small-interfering RNAs (siRNAs) specific for Smad3 and Nox2/4 were applied. All Smad3 and Nox2/4 siRNAs suppressed the up-regulation of ROS production by TGF-β1 in atrial fibroblasts, but to a lesser extent in Nox2 siRNA-transfected cells ( Figure 2C ; Figure 3 in the the online-only Data Supplement). The specificity of siRNAs was documented by western blot (Figure 4 in the the online-only Data Supplement). Together, these experimental findings suggest that TGF-β1, via the activation of Smad3, may induce stronger Nox4-derived ROS production in atrial fibroblasts.
Nox4 Is Involved in TGF-β1-Induced AtrialVentricular Difference
The next experiments were designed to assess the potential role of Nox4 in differential extracellular matrix protein responses of atrial fibroblasts. The effect of TGF-β1 on increasing collagen I and fibronectin expression was abolished by Nox4 inhibitors (DPI and plumbagin), but not by Nox2 inhibitor (gp91-dstat; Figure 3A ). Furthermore, transfection of both Nox4 and Smad3 siRNAs, but not Nox2 siRNA, attenuated TGF-β1-induced upregulation of collagen I and fibronectin in atrial fibroblasts (Figure 3B and 3C ). The fact that the difference between atrial and ventricular fibroblasts in response to TGF-β1 can be blocked by Nox4 and Smad3 inhibitors implies the potential role of Nox4 and Smad3 in mediating atrial-selective responses.
Previous studies demonstrate a crosstalk between NADPH oxidases and Smad in mediating TGF-β-induced differentiation of cardiac and renal fibroblasts. 18, 20, 21 The next experiments investigated whether NADPH oxidases are involved in TGF-β-induced activation of Smad3, including its phosphorylation and nuclear translocation. Pretreatment of both fibroblasts with Nox4 inhibitors and transfection of Nox4 siRNA prevented TGF-β1-stimulated phosphorylation of Smad3 ( Figure 3A-3C) . Transfection of Smad3 siRNA also suppressed the up-regulation of Nox4 in TGF-β1-treated fibroblasts ( Figure 3B and 3C) . Furthermore, in a gain-of-function study, we transfected fibroblasts with a wild-type Nox4 plasmid to overexpress Nox4. Overexpression of Nox4 in atrial fibroblasts augmented TGF-β-induced collagen I, fibronectin, and phospho-Smad3 expressions ( Figure 3D ), implicating that Nox4 and Smad3 are mutually regulated.
In agreement with its effect on Smad3 phosphorylation, TGF-β1 promoted more prominent nuclear translocation of Smad3 in atrial than in ventricular fibroblasts (4.1±0.3 versus 2.7±0.1 fold; P<0.05; Figure 4A and 4B). Treatment of both fibroblasts with Nox4 inhibitor (DPI) and transfection of Nox4 siRNA attenuated TGF-β1-induced nuclear translocation of Smad3, with more inhibitory effect on atrial fibroblasts (75.8±5.8% versus 45.4±8.1% for DPI; 49.5±2.9% versus 37.2±19.3% for Nox4 siRNA transfection, respectively; P<0.05; Figure 4A and B). These findings provide further evidence that there is a crosstalk between NADPH oxidases and Smad in TGF-β signaling.
Nox4 Mediates TGF-β1-Induced Atrial-Ventricular Difference in Collagen Transcriptional Activity
Because there is difference between atrial and ventricular fibroblasts in TGF-β1-induced collagen expression, the following experiments were designed to assess the regulatory level in determining this difference. At the transcriptional level, TGF-β1 concentration dependently increased collagen I mRNA level and its promoter activity in atrial and ventricular fibroblasts but to a lesser extent in ventricular fibroblasts ( Figure 5A and 5B). Furthermore, the promoting effect of TGF-β1 on collagen transcriptional activity could be blocked by Nox4 inhibition, including DPI, plumbagin, and Nox4 siRNA transfection (Figure 5B) . At the post-transcriptional level, the half-time of collagen I mRNA remained unaffected by TGF-β1 treatment in both fibroblasts, suggesting that changes in mRNA stability were not involved ( Figure 5 in the online-only Data Supplement). These experimental results point to Nox4-dependent transcriptional regulation as the basis of the greater response of collagen protein expression to TGF-β1 in atrial fibroblasts.
Previous studies indicate that the TGF-β1-Smad pathway is operated via the activation of genes with Smad4-binding elements in their promoter regions. 17 Bioinformatic analysis identified 2 putative Smad4-binding elements in the promoter region The expression of collagen I mRNA was evaluated by real-time reverse-transcription polymersae chain reaction (PCR) as described in Materials and Methods. B, A schematic linear map of the putative 2 SBEs at the 5' end point of the collagen I gene is shown in the upper panel. Growth-arrested cardiac fibroblasts were pretreated with Nox4 inhibitors and transfected with indicated siRNAs and plasmid containing collagen I promoter and subsequently treated with or without TGF-β1 for 24 hours. C, A schematic linear map of the putative 2 SBEs at the 5' end point of the collagen I gene and its mutated luciferase (Luc) constructs are shown in the left. Growth-arrested cardiac fibroblasts were transiently transfected with mutants of the promoter constructs and treated with or without 5 ng/mL TGF-β1 for 24 hours. The luciferase activity was assayed as described in Methods. Each value (mean±SE; n=4) is expressed as a fold of luciferase activity relative to the control condition. D, Chromatin immunoprecipitation assays were performed from soluble chromatins of cardiac fibroblasts treated with or without 5 ng/mL TGF-β1 for 24 hours, and immunoprecipitated with antibodies against Smad4, or nonspecific IgG. A representative PCR at 40 cycles of amplification using primers covering the collagen I promoter is shown. Bottom, Real-time PCR was used to quantify the PCR signals. The picture is a representative of 4 independent experiments. P<0.05; *, †represent the significant differences among groups. DPI indicates diphenyleneiodonium; IgG, Immunoglobulin G; Nox, nicotinamide adenine dinucleotide phosphate oxidase; si, small interfering; SBE, Smad4-binding elements; and TGF-β1 indicates transforming growth factor β1.
of collagen I gene. Mutation analysis of the collagen I promoter showed that TGF-β1-increased transcriptional activity was only evident when the promoter constructs contained the proximal Smad4-binding element ( Figure 5C ). To directly test in vivo binding of Smad4 to the collagen I promoter, chromatin immunoprecipitation assay was performed using a specific Smad4 antibody. TGF-β1 caused significantly larger amount of Smad4 bound to the collagen I promoter in atrial than in ventricular fibroblasts (9.2±0.5 versus 5.5±0.2 fold; P<0.05; Figure 5D ). Transfection of Nox4 siRNA reduced TGF-β1-induced binding of Smad4 to the collagen I promoter in atrial fibroblasts but to a less extent in ventricular fibroblasts (39.2±3.7% versus 15.9±5.5%; P<0.05; Figure 5D ). These experimental results document that TGF-β1/ Smads signaling is more sensitive to Nox4 inhibition in atrial than in ventricular fibroblasts.
Proliferative Response to TGF-β1 Is Similar Between Atrial and Ventricular Fibroblasts
In addition to the accumulation of extracellular matrix, increased cell numbers of fibroblasts may contribute to the development of myocardial fibrosis. 2 We, therefore, compared proliferation and viability between atrial and ventricular fibroblasts in response to TGF-β1. BrdU assay showed that TGF-β1 speeded cell proliferation in a similar rate between atrial and ventricular fibroblasts ( Figure 6 in the online-only Data Supplement). MTT assay demonstrated that cell viability was not different between atrial and ventricular fibroblasts exposed to TGF-β1 ( Figure 7 in the online-only Data Supplement).
TGF-β1 Responsiveness and Nox4 Expression in the Atria of Transgenic Mice With Cardiac Overexpression of TGF-β1
Previous study in the MHC-TGFcys33ser transgenic mice showed that the degree of myocardial fibrosis is more severe in atrium than in ventricle. 5, 6 Using the same model, we assessed TGF-β1 and Nox4 expression changes in vivo. In agreement with previous study, 5, 6 confocal immunohistochemistry revealed that the extent of collagen deposition was greater in atria than in ventricles ( Figure 6A and 6B) . Although TGF-β1 was both increased in the atria and ventricles of MHC-TGFcys33ser transgenic mice, the relative collagen to TGF-β1 ratio was significantly higher in atria than in ventricles ( Figure 6A-6C ). These results suggested that an increased responsiveness of TGF-β1 contributes to greater collagen deposition in the atria of MHCTGFcys33ser transgenic mice. Furthermore, ROS production and Nox4 expression in fibroblasts (identified by colocalization with vimentin), NADPH activity, and Smad3 phosphorylation were more prominent in atria than in ventricles (Figures 7 and 8 ; Figure 8 in the online-only Data Supplement). In contrast with Nox4, Nox2 expression exhibited no atrial-ventricular difference in MHC-TGFcys33ser transgenic mice (Figure 8 ; Figure 9 in the online-only Data Supplement). In addition, these changes have no left-right difference (Figures 6 and 7) . These in vivo data are compatible with in vitro findings of differential atrialventricular fibroblast responses of Nox4 and ROS to TGF-β1.
Discussion
The main findings of this study are as follows: (1) atrial fibroblasts are more responsive to TGF-β1 with respect to the expression of extracellular matrix proteins (collagen and fibronectin), especially at the transcriptional level, (2) TGF-β1 provokes more intense oxidative stress and promotes more active Smad signaling in atrial than in ventricular fibroblasts, which is mediated by the differential atrial-ventricular expression of Nox4, (3) Nox4-derived oxidative stress is involved in TGF-β1-induced up-regulation of collagen transcription, which accounts for the differential atrial-ventricular collagen expression in response to TGF-β1, and (4) in transgenic mice with cardiac overexpression of TGF-β1, the atrial-ventricular difference in collagen expression parallels that of TGF-β1 responsiveness and Nox4 expression.
We demonstrated that TGF-β1 increased the transcriptional activity of collagen and activated the Smad signaling in atrial fibroblasts. TGF-β1 also stimulated more Nox4 expression in atrial than in ventricular fibroblasts, which was reflected by a stronger ROS production. Furthermore, Nox4 inhibitors attenuate TGF-β1-dependent Smad signaling cascade, including activation of Smad3 and binding of Smad4 to the collagen promoter. Therefore, we conclude that the higher production of Nox4-derived ROS induced by TGF-β1 is essential for the discrepant atrial-ventricular collagen expression in cardiac fibroblasts.
The different characteristics in atrial-ventricular remodeling have been the subject of intensive investigation. [3] [4] [5] [6] [7] [8] Atriaselective fibrosis was found in TGF-β1-overexpressing mice. 5, 6 In dogs with tachypacing-induced heart failure, fibrosis is more substantial in left atrium than in left ventricle.
3,4 A recent study shows that atrial fibroblasts behave differently from ventricular fibroblasts in either in vitro or in vivo experiment. 4 In comparison with ventricular fibroblasts, atrial fibroblasts respond greatly to growth factors in its proliferative activity. This atria-selective response is attributed to platelet-derived growth factor. 4 Our study further demonstrated that Nox4-derived ROS significantly contributes to the atria-specific diversity. These findings implicate that TGF-β1 alone is not sufficient to cause fibrosis and Nox4-dependent ROS generation may potentiate the effect of TGF-β1 to promote fibrosis.
Previous studies demonstrate a crosstalk between NADPH oxidases and Smad in mediating TGF-β-induced differentiation of cardiac fibroblasts. 18, 20, 21 In this study, we provide further evidence that Nox4 participates in TGF-β/Smad signaling Figure 7 . A, C, and E, An identical paradigm was followed as described in Figure 6 . Representative confocal images show ROS production, Nox4 expression, and Smad3 phosphorylation in the atria and ventricles of MHC-TGFcys33ser transgenic mice compared with controls. B, D, and F, Relative intensities of ROS, Nox4 staining, and nuclear translocation of Smad3 in vimentin-expressing area are quantified. Data are mean±SE (a total of >3 fields and 30 cells with scanning and averaging). P<0.05; *the different symbol represents the significant differences among groups. LA indicates left atrium; LV, left ventricle; RA, right atrium; ROS, reactive oxygen species; RV, right ventricle; TGF, transforming growth factor; and WT, wild-type.
to induce differential atrial-ventricular collagen expression. Both Smad and Nox4 are essential for the up-regulation of collagen expression by TGF-β1 because both inhibitors may block this process. TGF-β1 induces only modest increase in phospho-Smad3 in ventricular fibroblasts, which accounts for the lower transcriptional activity and expression of collagen. The discrepancy in Nox4 expression and ensuing ROS production may contribute to the differential atrial-ventricular expression of phospho-Smad3 in response to TGF-β1.
NADPH oxidase-derived ROS production plays an important role in cardiovascular pathophysiology. Both Nox2 and Nox4 are expressed in cardiac fibroblasts and contribute to cardiac fibrosis. 19 Nox2 is involved in angiotensin II-and pressure overload-induced cardiac fibrosis, which is significantly attenuated in Nox2 −/− mice taking infusion of angiotensin II 22 or aortic constriction. 23 A recent study also shows that Nox2 −/− mice with myocardial infarction exhibit less cardiac fibrosis than wild-type mice. 24 Because Nox4 does not require cytosolic factors, such as p47 phox , p67 phox , and the small GTPase Rac for its activation, its expression level may fully determine the ROS production. [25] [26] [27] Recent studies have demonstrated that Nox4 is up-regulated in the heart by hypertrophic stimuli and presents a major source of oxidative stress in the failing heart. [25] [26] [27] Cardiac-specific Nox4 −/− mice exhibit significant attenuation of cardiac hypertrophy and fibrosis during pressure overload compared with wild-type mice. 25 In contrast, overexpression of Nox4 in mouse hearts exacerbates cardiac dysfunction and fibrosis in response to pressure overload. 25, 26 However, another study provides contradictory results. 27 Because most previous studies focus on ventricular fibrosis, our study has extended our knowledge about the role of NADPH oxidases, especially Nox4, in atrial fibrosis. Actually, numerous clinical and experimental studies have associated oxidative stress and TGF-β with AF. 18, 20 Nox2 has been shown to contribute to ROS production in the atria of AF patients, whereas the role of Nox4 remains unclear in AF. [9] [10] [11] [12] [13] [14] [15] [16] Our study showed that Nox4 mediates the effect of TGF-β1 in atrial fibroblasts implicating that Nox4 participates in atrial structural remodeling as a result of atrial fibrosis. The minor role of Nox2 in TGF-β1-induced atrial-ventricular differences may represent a cell-specific response in cardiac fibroblasts, which is in accordance with previous studies. 18 Previous studies indicate that atrial fibrosis is prominent in transgenic mice with cardiac overexpression of TGF-β1, which may make it an ideal model for studying the pathogenesis of AF. 5, 6 Despite comparable overexpression of TGF-β1 in the atria and ventricles of transgenic mice with cardiac overexpression of TGF-β1, we found that the ratio of collagen to TGF-β1 increases in the atria compared with ventricles. Because TGF-β1 is the key contributor to collagen production in the heart, it is conceivable that the responsiveness of collagen to TGF-β1 is greater in the atria. The involvement of Nox4, but not Nox2, in the responsive differences between atria and ventricles is documented by a higher expression of Nox4 in the atria. Nevertheless, because pathological changes other than atrial fibrosis are also involved in the pathogenesis of AF, 1, 2 whether the inference obtained from these transgenic mice can be applied to AF management needs to be further clarified.
TGF-β1 is well-known to promote extracellular matrix protein production from cardiac fibroblasts in vitro. We found that TGF-β1 did not induce collagen production in ventricular fibroblasts, which conflicts with previous studies. The explanation for this discrepancy is that we apply TGF-β1 in 10% fetal bovine serum, rather than the fetal bovine serum-free cultural conditions used by other groups. 28, 29 The effect of TGF-β1 on fibroblast proliferation also contradicts some of previous studies. Burstein's study in dogs reports that there are significant atrial-ventricular discrepancies with greater proliferative responses in atrial fibroblasts, 4 which is inconsistent with a mouse study 5 and our study. We do not find that TGF-β1 stimulates atrial-ventricular differences in fibroblast proliferation and viability. Species differences or discrepancies in experimental methods may account for this inconsistency.
